PB0458 - Rivaroxaban for management of Superficial Vein Thrombosis

Background: Superficial venous thrombosis (SVT) is associated with increased risk of DVT/PE. In 2015 we introduced an SVT treatment pathway in line with BSH guidelines (LMWH or fondaparinux) and Oct 2019 amended this pathway including rivaroxaban 10mg daily

Aims: To assess the efficacy and safety of introducing rivaroxaban for the management of SVT

Methods: Retrospective case-notes review of UHW DVT Clinic, Oct 2019 –Jan 2022, patients with SVT >3cm from the SFJ who received anticoagulation. Outcomes: SVT recurrence, DVT, PE within 90 days of anticoagulation and safety outcomes major or clinically relevant non-major bleeding while on anticoagulation.

Results: 4905 scans, 17% (757/4905) positive for venous thrombosis, 21% SVT (157/757): age 26 – 92 years; 56% (88) female and 44% (69) male. 129 (82%) SVT patients received rivaroxaban with no recurrences and 28 (18%) received LMWH (6%), fondaparinux 16 (10%) or serial imaging 3 (2%) due to malignancy (4), pregnancy/post-partum (11), patient-choice (7), drug-drug interaction (2), allergy (1), contra-indication (1). Risk factors for SVT: 107 (68.2%) varicose veins, 56 (35.7%) BMI > 30, 54 (34.4%) Age > 65, 37 (23.6%) previous VTE/SVT, 17 (10.8%) family history VTE, 10 (6.4%) COCP/HRT.

Conclusion(s): 82% (129) patients with SVT >3cm from the SFJ were treated with rivaroxaban 10mg OD, 101 (78%) received treatment for 6 weeks and then stopped with no recurrent event up to 90 days and 2 (1.6%) CRNMBs. These results suggest that rivaroxaban is a safe, effective treatment for the management of superficial vein thrombosis